Generic Products (September 2018)

MARKETED BY: Amerigen Pharmaceuticals

COMPARE TO: Targretin

INDICATION: Amerigen has launched its newly approved retinoid, bexarotene, as an AB-rated generic equivalent to Targretin to treat cutaneous T-cell lymphoma manifestations in patients who have not responded to other treatment methods. Retinoids, such as bexarotene, are linked to birth defects and are therefore not recommended for treatment during pregnancy.

DOSAGE FORM: Capsules

FOR MORE INFORMATION: amerigenpharma.com

VIGADRONE FOR ORAL SOLUTION

MARKETED BY: Upsher-Smith Laboratories LLC

COMPARE TO: Sabril

INDICATION: The FDA has approved Vigadrone (vigabatrin) for Oral Solution with an AA rating as a generic alternative to Sabril. Vigadrone treats infantile spasms in infants, where the benefit of treatment outweighs the associated risk of vision loss, and refractory complex partial seizures in patients who are 10 years or older and have not responded to alternative treatment. Vigadrone is an adjunctive therapy that should not be used as a first- line treatment.

DOSAGE FORM: Oral solution

FOR MORE INFORMATION: upsher-smith.com

METFORMIN HYDROCHLORIDE

MARKETED BY: Sun Pharmaceutical Industries Ltd

COMPARE TO: GlumetzaINDICATION: SunPharma has launched metformin hydrochloride extended-release tablets as a generic equivalent to Glumetza to improve glycemic control in adults with type 2 diabetes.

DOSAGE FORM: Oral tablets, 500 and 1000 mg

FOR MORE INFORMATION: sunpharma.com

RIVASTIGMINE TRANSDERMAL SYSTEM

MARKETED BY: Mylan N.V.

COMPARE TO: Exelon Patch

INDICATION: Mylan has launched a generic equivalent to the Exelon Patch to treat dementia in patients with mild, moderate, or severe Alzheimer disease and mild to moderate Parkinson disease. The transdermal patch is offered in doses of 4.6, 9.5, and 13.3 mg per 24-hour period.

DOSAGE FORM: Transdermal patch

FOR MORE INFORMATION: mylan.com